Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections

Area of Science:

• Microbiology
• Infectious Diseases
• Bacteriology

Background:

• Antibiotic resistance is a growing global health threat, particularly in treating infections caused by the Burkholderia cepacia complex (BCC).
• Phage therapy, using bacteriophages to target specific bacteria, is being explored as an alternative to antibiotics for resistant pathogens.

Purpose of the Study:

• To evaluate the efficacy of aerosolized phage therapy in treating experimental respiratory infections caused by Burkholderia cenocepacia, a species within the BCC.
• To compare the effectiveness of aerosol delivery versus intraperitoneal injection for phage therapy against BCC infections in a murine model.

Main Methods:

• Murine models of B. cenocepacia respiratory infection were established using nebulized bacteria.
• Mice were treated with B. cenocepacia-specific phages administered via aerosol inhalation or intraperitoneal injection.
• Bacterial and phage titers in lung tissue were quantified 2 days post-treatment.

Main Results:

• Aerosolized phage therapy significantly reduced bacterial loads in the lungs of infected mice.
• Intraperitoneal phage administration did not result in significant bacterial load reduction, despite detectable phage particles in lung tissue.
• Differential efficacy was observed between the two delivery methods, indicating route-dependent phage activity.

Conclusions:

• Aerosol delivery of bacteriophages is an effective strategy for treating antibiotic-resistant bacterial respiratory infections, including those caused by BCC.
• Phage therapy shows potential as a viable treatment option for challenging infections where conventional antibiotics are ineffective.
• The route of phage administration is a critical factor influencing therapeutic outcomes in vivo.